What would make a doctor refuse to prescribe a GLP-1?
A doctor may decline to prescribe a GLP-1 receptor agonist if a patient has certain medical contraindications, does not meet prescribing criteria, or if the potential risks outweigh the expected benefits for that individual. Common reasons include a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), a history of severe pancreatitis, severe gastrointestinal disease, pregnancy or planned pregnancy, or evidence of an active eating disorder. Prescribing decisions also depend on whether a patient meets the clinical thresholds for the specific licensed indication — such as BMI requirements for weight management — and whether safer or more appropriate alternatives exist. Because every case is different, suitability is always a clinical decision made by a qualified doctor after reviewing a patient's full medical history.
Recognised medical contraindications
Certain conditions are listed in the prescribing information for GLP-1 receptor agonists as contraindications or reasons for extreme caution. These typically include:
- Personal or family history of medullary thyroid carcinoma (MTC) — preclinical studies in rodents identified a thyroid C-cell tumour signal, and current labelling contraindicates use in patients with this history.
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) — due to the associated elevated risk of MTC.
- Known hypersensitivity to the active substance or any excipient in the formulation.
- History of severe or recurrent pancreatitis — although the overall risk is low, a prior episode may prompt a clinician to avoid the medication class.
These contraindications are drawn from the Summary of Product Characteristics (SmPC) and are non-negotiable in most clinical settings.
Eligibility and prescribing criteria
Even without a contraindication, a doctor may determine that a patient does not meet the licensed or commissioning criteria for a GLP-1 receptor agonist. Factors include:
- BMI thresholds — for weight-management indications, UK and international guidelines generally set minimum BMI thresholds (often ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity). A patient below these thresholds may not qualify.
- Inadequate prior lifestyle measures — many prescribing frameworks require evidence that diet and exercise interventions have been attempted before pharmacotherapy is offered.
- Type 2 diabetes treatment pathways — a clinician may consider a GLP-1 receptor agonist premature if earlier-line therapies have not yet been trialled, in line with NICE or local formulary guidance.
Other clinical concerns that may influence the decision
Beyond formal contraindications and eligibility criteria, a prescriber may exercise clinical judgement to withhold a prescription in scenarios such as:
- Pregnancy, breastfeeding, or planned conception — GLP-1 receptor agonists are generally not recommended during pregnancy, and discontinuation is typically advised well before conception.
- Severe gastroparesis or significant gastrointestinal disease — because GLP-1 receptor agonists delay gastric emptying, they may worsen certain gastrointestinal conditions.
- Active or recent eating disorders — the appetite-suppressing effects could complicate recovery; a clinician may seek psychiatric or specialist input first.
- Severe renal impairment — some agents in the class require dose adjustment or are not recommended at very low eGFR levels.
- Drug interactions or polypharmacy concerns — delayed gastric emptying may affect the absorption of other oral medications; a prescriber will weigh this risk.
- Patient unable to commit to monitoring — ongoing clinical review is an expected part of treatment, and a lack of follow-up capability may lead a clinician to defer prescribing.
The role of clinical judgement
It is important to understand that prescribing is not a simple checklist exercise. A doctor weighs the totality of a patient's health profile — including comorbidities, mental health, medication history, and personal preferences — before deciding whether a GLP-1 receptor agonist is appropriate. A refusal to prescribe does not necessarily mean the medication will never be suitable; circumstances and evidence evolve, and a clinician may revisit the decision at a later date. Patients who have questions about why a prescription was declined are encouraged to discuss the reasoning openly with their doctor.
FAQ
Q: Can a doctor refuse to prescribe a GLP-1 even if my BMI is high enough? A: Yes. Meeting a BMI threshold is only one part of the assessment. A doctor will also consider contraindications, other medical conditions, current medications, and whether lifestyle interventions have been adequately explored. Eligibility criteria alone do not guarantee a prescription.
Q: If one doctor refuses, should I seek a prescription elsewhere? A: It is always your right to seek a second opinion. However, the same clinical standards and contraindications will apply regardless of the prescriber. It is generally more productive to understand and discuss the specific reasons behind the initial decision with your doctor.
Q: Are the reasons for refusal the same for every GLP-1 receptor agonist? A: Most contraindications — such as MTC history and MEN 2 — are class-wide. However, individual agents may have additional or slightly different cautions (for example, relating to renal dosing or formulation-specific allergies). A qualified clinician can explain which considerations apply to a specific medication.